Biosimilars for Hematologic Malignancies: Dissecting Real-World Evidence and Barriers to Utilization
Dr. Charles L. Bennett; Dr. Marc L. Fishman; Dr. Kevin Knopf
The Use of Biosimilars in Hematology/Oncology Practice
Dr. Charles Bennett, Dr. Marc Fishman, and Dr. Kevin Knopf
Are there any concerns or precautions clinicians should be aware of when switching a patient from IV daratumumab to subcutaneous?
Saad Z. Usmani, MD, FACP
What has been the overall impact of safety and efficacy in four-drug regimens compared to three-drug regimens?
Sagar Lonial, MD, FACP
FAQ
Developments in Newly Diagnosed Multiple Myeloma:
Considerations for Improved Patient Outcomes
Coming Soon – On Demand Program
Earn CME/CPE/CNE Credit!
Sagar Lonial, MD, FACP
